Last updated on December 2018

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)


Brief description of study

This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The cisplatin combination expansion portion will evaluate the anti tumor activity of PF 05212384 plus cisplatin in patients with TNBC in 2 separate Arms (Arm 1 and Arm 2).

Clinical Study Identifier: NCT01920061

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

MUSC Health East Cooper
Mount Pleasant, SC United States
1.13miles
  Connect »

Pfizer CT.gov Call Center

Medical University of South Carolina
Charleston, SC United States
7.59miles
  Connect »

Pfizer CT.gov Call Center

Medical University of South Carolina/ University Hospital
Charleston, SC United States
7.59miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.